Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF) pipeline, particularly its lead candidates, SION-719 and SION-451, which work by stabilising the nucleotide‐binding domain 1 domain of the CF transmembrane conductance regulator (CFTR) protein.
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF) pipeline, particularly its lead candidates, SION-719 and SION-451, which work by stabilising the nucleotide‐binding domain 1 domain of the CF transmembrane conductance regulator (CFTR) protein.
What's Your Reaction?
